Pathwork Diagnostics, a developer of oncology diagnostics assays, has named Lee McCracken as the company's new chief executive officer (CEO).
Pathwork Diagnostics board chairman Peter Klemm said,"Lee, with his considerable leadership and corporate development experience, is an outstanding choice to lead Pathwork to the next level of success."
Pathwork Diagnostics CEO Lee McCracken said he is pleased to join the company at the exciting time in the company’s history.
"I believe the Tissue of Origin Test is positioned to become the standard of care for difficult-to-diagnose cancer tumors," McCracken added.
"Furthermore, Pathwork’s proprietary informatics platform – which enabled the creation of the Tissue of Origin Test – has significant potential for developing new products.
"I look forward to leading the company’s next stage of growth."
Previously, McCracken served as business development corporate head at Prometheus Laboratories, as pharmaceutical business development senior vice president at Diversa as well held various leadership roles at GenStar Therapeutics, CombiChem and Allergan Americas.